Latest Sinovac Biotech (SVA) Headlines Sinovac
Post# of 7
Posted On: 03/13/2014 3:05:38 AM
Latest Sinovac Biotech (SVA) Headlines
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 Unaudited Financial Results
PR Newswire - Wed Mar 12, 5:00AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and whole year ended December 31, 2013, after market closes on Wednesday, March 19, 2014 EDT. The Company will host a conference call prior to the market opening on Thursday, March 20, 2014, at 8:00 a.m. EDT (Thursday, March 20, 2014 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
Sinovac's EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine
PR Newswire - Wed Feb 26, 4:01PM CST
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary Enterovirus 71 ("EV71") vaccine have been published online in the February 27th issue of The New England Journal of Medicine ("NEJM"). The clinical results showed the efficacy of the vaccine against EV71-associated hand, foot and mouth disease ("HFMD"), or herpangina, was 94.8% among infants and young children and an anti-EV71 neutralizing antibody titer of 1:16 was associated with protection against EV71 associated HFMD or herpangina. As outlined in the NEJM article, Sinovac's vaccine also demonstrated a 100% efficacy rate against EV71-associated hospitalization and against HFMD with neurologic complications, the main cause of fatalities.
4 Stocks Under $10 in Breakout Territory
at The Street - Wed Feb 12, 5:30AM CST
These under-$10 stocks are within range of triggering breakout trades.
Sinovac Biotech Ltd submits CTA with the CFDA to commence human clinical trials of its H7N9 avian influenza vaccine
M2 - Thu Jan 30, 3:10AM CST
Biopharmaceutical company Sinovac Biotech Ltd (NasdaqGS:SVA) reported on Wednesday the submission of a Clinical Trial Application(CTA) with the China Food and Drug Administration (CFDA) to begin human clinical trials of its vaccine against Avian influenza A(H7N9) virus.
Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine against Avian Influenza A(H7N9) Virus
PR Newswire - Wed Jan 29, 6:07AM CST
Sinovac Biotech Ltd. (Nasdaq:SVA), a leading provider of biopharmaceutical products in China, announced today that it has submitted a Clinical Trial Application(CTA) with the China Food and Drug Administration (CFDA) to commence human clinical trials for its vaccine against Avian influenza A(H7N9) virus. The CTA was officially accepted by CFDA on January 29, 2014. Incidence rates for H7N9 continue to increase in China, with 153 H7N9 Human infectious cases reported in 2013, according to the World Health Organization (WHO). In January 2014, 96 H7N9 cases were reported in China, including 20 fatalities.
The Latest Rubella Pipeline Review
M2 - Mon Jan 27, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/bp2w2h/rubella) has announced the addition of the "Rubella - Pipeline Review, H2 2013" report to their offering. 'Rubella - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rubella, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rubella. Scope - A snapshot of the global therapeutic scenario for Rubella. - A review of the Rubella products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rubella pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Tables & Figures Introduction Rubella Overview Rubella - Pipeline Products Glance Rubella - Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Zydus Cadila Healthcare Limited - Cadila Pharmaceuticals Ltd. - Sinovac Biotech Ltd. - Beijing Tiantan Biological Products Co., Ltd. Rubella - Therapeutics Assessment Drug Profiles measles, mumps and rubella vaccine (live) GSK-208136 Live Rubella Vaccine Measles and Rubella Vaccine Vaccine For Live Measles, Mumps and Rubella Rubella Vaccine MMR Varicella Vaccine Rubella - Recent Pipeline Updates Featured News & Press Releases For more information visit http://www.researchandmarkets.com/research/bp2w2h/rubella
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Shares of SVA Up 109.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jan 06, 4:31PM CST
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on December 21st, 2012 at $3.01. In approximately 13 months, Sinovac Biotech has returned 109.30% as of today's recent price of $6.30.
Sinovac Biotech Shares Up 88.7% Since SmarTrend's Buy Recommendation (SVA)
Comtex SmarTrend(R) - Wed Dec 11, 9:35AM CST
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on December 21st, 2012 at $3.01. In approximately 12 months, Sinovac Biotech has returned 88.70% as of today's recent price of $5.68.
Enterovirus Infections - Pipeline Review, H2 2013
M2 - Wed Dec 11, 2:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/dh9v25/enterovirus) has announced the addition of the "Enterovirus Infections - Pipeline Review, H2 2013" report to their offering. 'Enterovirus Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Enterovirus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterovirus Infections. Scope - A snapshot of the global therapeutic scenario for Enterovirus Infections. - A review of the Enterovirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterovirus Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Enterovirus Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Enterovirus Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Sinovac Biotech Co., Ltd. Beijing Minhai Biotechnology Co., Ltd For more information visit http://www.researchandmarkets.com/research/dh...nterovirus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Haemophilus Influenzae Type b Infections - Pipeline Review, H2 2013
M2 - Tue Dec 10, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/xsq9ff/haemophilus) has announced the addition of the "Haemophilus Influenzae Type b Infections - Pipeline Review, H2 2013" report to their offering. 'Haemophilus Influenzae Type b Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Haemophilus Influenzae Type b Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Type b Infections. Scope - A snapshot of the global therapeutic scenario for Haemophilus Influenzae Type b Infections. - A review of the Haemophilus Influenzae Type b Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Haemophilus Influenzae Type b Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Haemophilus Influenzae Type b Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Haemophilus Influenzae Type b Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned GlaxoSmithKline plc Biological E. Limited Novartis AG LG Life Sciences, Ltd Panacea Biotec Limited Sinovac Biotech Ltd. Indian Immunologicals Limited Beijing Minhai Biotechnology Co., Ltd For more information visit http://www.researchandmarkets.com/research/xs...aemophilus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Why Sinovac, Pluristem, and Synta Could Be Worth Watching Today
Leo Sun, The Motley Fool - Motley Fool - Wed Nov 13, 8:22AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a...
Market Research: Diphtheria - Pipeline Review, H2 2013
M2 - Wed Nov 13, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/6dvgsh/diphtheria) has announced the addition of the "Diphtheria - Pipeline Review, H2 2013" report to their offering. 'Diphtheria - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diphtheria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diphtheria. Scope - A snapshot of the global therapeutic scenario for Diphtheria. - A review of the Diphtheria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diphtheria pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Sanofi-Aventis GlaxoSmithKline plc Takeda Pharmaceutical Company Limited Biological E. Limited Zosano Pharma, Inc. Green Cross Corporation LG Life Sciences, Ltd Panacea Biotec Limited Sinovac Biotech Co., Ltd. Serum Institute of India Limited Indian Immunologicals Limited Beijing Minhai Biotechnology Co., Ltd For more information visit http://www.researchandmarkets.com/research/6dvgsh/diphtheria About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Sinovac Reports Unaudited Third Quarter 2013 Financial Results
PR Newswire - Tue Nov 12, 5:00PM CST
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter financial results for for the three and nine months ended September 30, 2013.
Uptrend Call Working As Sinovac Biotech Stock Rises 95.2% (SVA)
Comtex SmarTrend(R) - Tue Nov 12, 4:40PM CST
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on December 21st, 2012 at $3.01. In approximately 11 months, Sinovac Biotech has returned 95.18% as of today's recent price of $5.88.
Market Research: Rabies - Pipeline Review, H2 2013
M2 - Mon Nov 11, 3:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/jg2s9p/rabies_pipeline) has announced the addition of the "Rabies - Pipeline Review, H2 2013" report to their offering. 'Rabies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rabies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rabies. Scope - A snapshot of the global therapeutic scenario for Rabies. - A review of the Rabies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rabies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Rabies. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Celltrion, Inc. KAKETSUKEN Novavax, Inc. Zydus Cadila Healthcare Limited Crucell N.V. Medicago Inc. NanoViricides, Inc. Kamada Ltd. Isconova AB. Sinovac Biotech Ltd. Serum Institute of India Limited Trellis Bioscience, Inc. Molecular Targeting Technologies, Inc. Prosetta Corporation Beijing Minhai Biotechnology Co., Ltd For more information visit http://www.researchandmarkets.com/research/jg...s_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Sinovac Receives Jiangsu Province Tender Award to Supply Inactivated Hepatitis Vaccine Healive(R) under Expanded Immunization Program
PR Newswire - Thu Nov 07, 6:00AM CST
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading China-based vaccine manufacturer, announced today that it has been selected by the Jiangsu Centers for Disease Control and Prevention (Jiangsu CDC) to supply the Company's inactivated hepatitis A vaccine, Healive, under the Expanded Program of Immunization (EPI) in 2014 to the pediatric population in Jiangsu Province. The total volume of the tender is up to 1.8 million doses. As one of the two selected suppliers, Sinovac will supply 900,000 doses of Healive to Jiangsu province.
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 Unaudited Financial Results
PR Newswire - Wed Mar 12, 5:00AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and whole year ended December 31, 2013, after market closes on Wednesday, March 19, 2014 EDT. The Company will host a conference call prior to the market opening on Thursday, March 20, 2014, at 8:00 a.m. EDT (Thursday, March 20, 2014 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
Sinovac's EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine
PR Newswire - Wed Feb 26, 4:01PM CST
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary Enterovirus 71 ("EV71") vaccine have been published online in the February 27th issue of The New England Journal of Medicine ("NEJM"). The clinical results showed the efficacy of the vaccine against EV71-associated hand, foot and mouth disease ("HFMD"), or herpangina, was 94.8% among infants and young children and an anti-EV71 neutralizing antibody titer of 1:16 was associated with protection against EV71 associated HFMD or herpangina. As outlined in the NEJM article, Sinovac's vaccine also demonstrated a 100% efficacy rate against EV71-associated hospitalization and against HFMD with neurologic complications, the main cause of fatalities.
4 Stocks Under $10 in Breakout Territory
at The Street - Wed Feb 12, 5:30AM CST
These under-$10 stocks are within range of triggering breakout trades.
Sinovac Biotech Ltd submits CTA with the CFDA to commence human clinical trials of its H7N9 avian influenza vaccine
M2 - Thu Jan 30, 3:10AM CST
Biopharmaceutical company Sinovac Biotech Ltd (NasdaqGS:SVA) reported on Wednesday the submission of a Clinical Trial Application(CTA) with the China Food and Drug Administration (CFDA) to begin human clinical trials of its vaccine against Avian influenza A(H7N9) virus.
Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine against Avian Influenza A(H7N9) Virus
PR Newswire - Wed Jan 29, 6:07AM CST
Sinovac Biotech Ltd. (Nasdaq:SVA), a leading provider of biopharmaceutical products in China, announced today that it has submitted a Clinical Trial Application(CTA) with the China Food and Drug Administration (CFDA) to commence human clinical trials for its vaccine against Avian influenza A(H7N9) virus. The CTA was officially accepted by CFDA on January 29, 2014. Incidence rates for H7N9 continue to increase in China, with 153 H7N9 Human infectious cases reported in 2013, according to the World Health Organization (WHO). In January 2014, 96 H7N9 cases were reported in China, including 20 fatalities.
The Latest Rubella Pipeline Review
M2 - Mon Jan 27, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/bp2w2h/rubella) has announced the addition of the "Rubella - Pipeline Review, H2 2013" report to their offering. 'Rubella - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rubella, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rubella. Scope - A snapshot of the global therapeutic scenario for Rubella. - A review of the Rubella products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rubella pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Tables & Figures Introduction Rubella Overview Rubella - Pipeline Products Glance Rubella - Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Zydus Cadila Healthcare Limited - Cadila Pharmaceuticals Ltd. - Sinovac Biotech Ltd. - Beijing Tiantan Biological Products Co., Ltd. Rubella - Therapeutics Assessment Drug Profiles measles, mumps and rubella vaccine (live) GSK-208136 Live Rubella Vaccine Measles and Rubella Vaccine Vaccine For Live Measles, Mumps and Rubella Rubella Vaccine MMR Varicella Vaccine Rubella - Recent Pipeline Updates Featured News & Press Releases For more information visit http://www.researchandmarkets.com/research/bp2w2h/rubella
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Shares of SVA Up 109.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jan 06, 4:31PM CST
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on December 21st, 2012 at $3.01. In approximately 13 months, Sinovac Biotech has returned 109.30% as of today's recent price of $6.30.
Sinovac Biotech Shares Up 88.7% Since SmarTrend's Buy Recommendation (SVA)
Comtex SmarTrend(R) - Wed Dec 11, 9:35AM CST
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on December 21st, 2012 at $3.01. In approximately 12 months, Sinovac Biotech has returned 88.70% as of today's recent price of $5.68.
Enterovirus Infections - Pipeline Review, H2 2013
M2 - Wed Dec 11, 2:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/dh9v25/enterovirus) has announced the addition of the "Enterovirus Infections - Pipeline Review, H2 2013" report to their offering. 'Enterovirus Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Enterovirus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterovirus Infections. Scope - A snapshot of the global therapeutic scenario for Enterovirus Infections. - A review of the Enterovirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterovirus Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Enterovirus Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Enterovirus Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Sinovac Biotech Co., Ltd. Beijing Minhai Biotechnology Co., Ltd For more information visit http://www.researchandmarkets.com/research/dh...nterovirus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Haemophilus Influenzae Type b Infections - Pipeline Review, H2 2013
M2 - Tue Dec 10, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/xsq9ff/haemophilus) has announced the addition of the "Haemophilus Influenzae Type b Infections - Pipeline Review, H2 2013" report to their offering. 'Haemophilus Influenzae Type b Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Haemophilus Influenzae Type b Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Type b Infections. Scope - A snapshot of the global therapeutic scenario for Haemophilus Influenzae Type b Infections. - A review of the Haemophilus Influenzae Type b Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Haemophilus Influenzae Type b Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Haemophilus Influenzae Type b Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Haemophilus Influenzae Type b Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned GlaxoSmithKline plc Biological E. Limited Novartis AG LG Life Sciences, Ltd Panacea Biotec Limited Sinovac Biotech Ltd. Indian Immunologicals Limited Beijing Minhai Biotechnology Co., Ltd For more information visit http://www.researchandmarkets.com/research/xs...aemophilus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Why Sinovac, Pluristem, and Synta Could Be Worth Watching Today
Leo Sun, The Motley Fool - Motley Fool - Wed Nov 13, 8:22AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a...
Market Research: Diphtheria - Pipeline Review, H2 2013
M2 - Wed Nov 13, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/6dvgsh/diphtheria) has announced the addition of the "Diphtheria - Pipeline Review, H2 2013" report to their offering. 'Diphtheria - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diphtheria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diphtheria. Scope - A snapshot of the global therapeutic scenario for Diphtheria. - A review of the Diphtheria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diphtheria pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Sanofi-Aventis GlaxoSmithKline plc Takeda Pharmaceutical Company Limited Biological E. Limited Zosano Pharma, Inc. Green Cross Corporation LG Life Sciences, Ltd Panacea Biotec Limited Sinovac Biotech Co., Ltd. Serum Institute of India Limited Indian Immunologicals Limited Beijing Minhai Biotechnology Co., Ltd For more information visit http://www.researchandmarkets.com/research/6dvgsh/diphtheria About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Sinovac Reports Unaudited Third Quarter 2013 Financial Results
PR Newswire - Tue Nov 12, 5:00PM CST
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter financial results for for the three and nine months ended September 30, 2013.
Uptrend Call Working As Sinovac Biotech Stock Rises 95.2% (SVA)
Comtex SmarTrend(R) - Tue Nov 12, 4:40PM CST
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on December 21st, 2012 at $3.01. In approximately 11 months, Sinovac Biotech has returned 95.18% as of today's recent price of $5.88.
Market Research: Rabies - Pipeline Review, H2 2013
M2 - Mon Nov 11, 3:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/jg2s9p/rabies_pipeline) has announced the addition of the "Rabies - Pipeline Review, H2 2013" report to their offering. 'Rabies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rabies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rabies. Scope - A snapshot of the global therapeutic scenario for Rabies. - A review of the Rabies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rabies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Rabies. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Celltrion, Inc. KAKETSUKEN Novavax, Inc. Zydus Cadila Healthcare Limited Crucell N.V. Medicago Inc. NanoViricides, Inc. Kamada Ltd. Isconova AB. Sinovac Biotech Ltd. Serum Institute of India Limited Trellis Bioscience, Inc. Molecular Targeting Technologies, Inc. Prosetta Corporation Beijing Minhai Biotechnology Co., Ltd For more information visit http://www.researchandmarkets.com/research/jg...s_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Sinovac Receives Jiangsu Province Tender Award to Supply Inactivated Hepatitis Vaccine Healive(R) under Expanded Immunization Program
PR Newswire - Thu Nov 07, 6:00AM CST
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading China-based vaccine manufacturer, announced today that it has been selected by the Jiangsu Centers for Disease Control and Prevention (Jiangsu CDC) to supply the Company's inactivated hepatitis A vaccine, Healive, under the Expanded Program of Immunization (EPI) in 2014 to the pediatric population in Jiangsu Province. The total volume of the tender is up to 1.8 million doses. As one of the two selected suppliers, Sinovac will supply 900,000 doses of Healive to Jiangsu province.
(0)
(0)Sinovac Biotech (SVA) Stock Research Links
Scroll down for more posts ▼